Sodium‑glucose cotransporter 2 inhibitors (SGLT2i): renal implications
| datacite.rights | http://purl.org/coar/access_right/c_abf2 | spa |
| dc.contributor.author | Castañeda, Alejandrina M. | |
| dc.contributor.author | Dutra‑Rufato, Amanda | |
| dc.contributor.author | Juarez, Maria J. | |
| dc.contributor.author | Grosembacher, Luis | |
| dc.contributor.author | Gonzalez‑Torres, Henry | |
| dc.contributor.author | Musso, Carlos G. | |
| dc.date.accessioned | 2020-08-10T16:48:01Z | |
| dc.date.available | 2020-08-10T16:48:01Z | |
| dc.date.issued | 2020 | |
| dc.description.abstract | Type 2 diabetes mellitus (DM2) is a chronic condition that affects more than 400 million individuals worldwide. In DM2 patients, an appropriate glycemic control slows the onset and delays the progression of all its micro and macrovascular complications. Even though there are several glucose-lowering drugs, only approximately half of patients achieve glycemic control, while undesirable adverse effects (e.g., low serum glucose) normally affect treatment. Therefore, there is a need for new types of treatments. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have just been developed for treating DM2. Renal hyperfiltration as a marker of increased intraglomerular pressure in diabetic patients, and the role of renin–angiotensin– aldosterone system (RAAS) in this phenomenon have been studied. Nevertheless, RAAS blockade does not completely reduce hyperfiltration or diabetic renal damage. In this sense, the contribution of renal tubular factors to the hyperfiltration state, including sodium–glucose cotransporter (SGLT), has been currently studied. SGLT2i reduce proximal tubular sodium reabsorption, therefore increasing distal sodium delivery to the macula densa, causing tubule-glomerular feedback activation, afferent vasoconstriction, and reduced hyperfiltration in animal models. In humans, SGLT2i was recently shown to reduce hyperfiltration in normotensive, normoalbuminuric patients suffering from type 1 diabetes mellitus. In DM2 clinical trials, SGLT2 is associated with significant hyperfiltration and albuminuria reduction. The aim of this article is to compile the information regarding SGLT2i drugs, emphasizing its mechanism of renal repercussion. | eng |
| dc.format.mimetype | spa | |
| dc.identifier.doi | https://doi.org/10.1007/s11255-020-02585-w | |
| dc.identifier.issn | 15732584 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12442/6244 | |
| dc.language.iso | eng | eng |
| dc.publisher | Springer | eng |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | eng |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | eng |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
| dc.source | International Urology and Nephrology | eng |
| dc.source | Vol. 38 N° 8, (2020) | |
| dc.subject | SGLT2i | eng |
| dc.subject | Kidney | eng |
| dc.subject | Glucosuria | eng |
| dc.title | Sodium‑glucose cotransporter 2 inhibitors (SGLT2i): renal implications | eng |
| dc.type.driver | info:eu-repo/semantics/article | eng |
| dc.type.spa | Artículo científico | spa |
| dcterms.references | Halimi S, Vergès B (2014) Adverse effects and safety of SGLT-2 inhibitors. Diabetes Metab. 40(6 Suppl 1):S28–S34. https ://doi. org/10.1016/S1262 -3636(14)72693 -X | eng |
| dcterms.references | World Health Organization [Internet] (2018) https ://www.who. int/news-room/fact-sheet s/detai l/diabe tes. Accessed 28 Aug 2018 | eng |
| dcterms.references | Škrtić M, Cherney D (2015) Sodium–glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy. Curr Opin Nephrol Hypertens 24(1):96–103 | eng |
| dcterms.references | Poudel R (2013) Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition. Indian J Endocrinol Metab 17(4):588–593 | eng |
| dcterms.references | Gerich JE (2010) Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med 27(2):136–142 | eng |
| dcterms.references | Salvatore T, Carbonara O, Cozzolino D, Torella R, Nasti R, Lascar N, Sasso FC (2011) Kidney in diabetes: from organ damage target to therapeutic target. Curr Drug Metab 12(7):658–666. https ://doi. org/10.2174/13892 00117 96504 509 | eng |
| dcterms.references | Van Bommel E, Muskiet M, Tonneijck L, Kramer M, Nieuwdorp M, van Raalte D (2017) SGLT2 Inhibition in the diabetic kidney—from mechanisms to clinical outcome. Clin J Am Soc Nephrol. 12(4):700–710 | eng |
| dcterms.references | Komala MG, Panchapakesan U, Pollock C, Mather A (2013) Sodium glucose cotransporter 2 and the diabetic kidney. Curr Opin Nephrol Hypertens 22(1):113–119 | eng |
| dcterms.references | De Nicola L, Gabbai F, Liberti ME, Sagliocca A, Conte G, Minutolo R (2014) Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes. Am J Kidney Dis 64(1):16–24 | eng |
| dcterms.references | Gómez-Fernández P, Fernández-García D (2016) Renal safety profile of sodium-glucose type 2 cotransporter inhibitors and other safety data. Med Clin (Barc). 147(Suppl 1):44–48. https :// doi.org/10.1016/S0025 -7753(17)30625 -5 | eng |
| dcterms.references | Vallon V, Thomson S (2016) Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia 60(2):215–225 | eng |
| dcterms.references | Ferrannini E, Solini A (2012) SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol 8(8):495–502 | eng |
| dcterms.references | Tejedor-Jorge A (2016) Implicaciones hemodinámicas y renales de los inhibidores del cotransportador sodio-glucosa tipo 2 en el contexto de la diabetes mellitus tipo 2. Med Clín 147(S1):35–43. https ://doi.org/10.1016/S0025 -7753(17)30624 -3 | eng |
| dcterms.references | https ://doi.org/10.1016/S0025 -7753(17)30624 -3 14. Rajasekeran H, Cherney D, Lovshin JA (2017) Do effects of sodium–glucose cotransporter-2 inhibitors in patients with diabetes give insight into potential use in non-diabetic kidney disease? Curr Opin Nephrol Hypertens 26(5):358–367 | eng |
| dcterms.references | Ferrannini E (2017) Sodium-glucose co-transporters and their inhibition: clinical physiology. Cell Metab 26(1):27–38 | eng |
| dcterms.references | Panchapakesan U, Pegg K, Gross S, Komala M, Mudaliar H, Forbes J, Mather A (2013) Effects of SGLT2 inhibition in human kidney proximal tubular cells-renoprotection in diabetic nephropathy? PLoS One 8(2):e54442 | eng |
| dcterms.references | Cherney D, Perkins B (2014) Sodium-glucose cotransporter 2 inhibition in type 1 diabetes: simultaneous glucose lowering and renal protection? Can J Diabetes. 38(5):356–363 | eng |
| dcterms.references | Ferrannini E, Veltkamp S, Smulders R, Kadokura T (2013) Renal glucose handling: impact of chronic kidney disease and sodiumglucose cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes Care 36(5):1260–1265 | eng |
| dcterms.references | Jaikumkao K, Pongchaidecha A, Chatsudthipong V, Chattipakorn S, Chattipakorn N, Lungkaphin A (2017) The roles of sodiumglucose cotransporter 2 inhibitors in preventing kidney injury in diabetes. Biomed Pharmacother 94:176–187 | eng |
| dcterms.references | M, Escalante B (2012) Sodium-glucose cotransporter inhibition prevents oxidative stress in the kidney of diabetic rats. Oxid Med Cell Longev 2012:542042. https ://doi.org/10.1155/2012/54204 2 | eng |
| dcterms.references | Wanner C (2017).EMPA-REG OUTCOME: the nephrologist’s point of view. 120(1S):S59–S67. https ://doi.org/10.1016/j.amjca rd.2017.05.012 | eng |
| dcterms.references | Heerspink H, Kosiborod M, Inzucchi S, Cherney D (2018) Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int 94(1):26–39 | eng |
| dcterms.references | Brady JA, Hallow KM (2018) Model-based evaluation of proximal sodium reabsorption through SGLT2 in health and diabetes and the effect of inhibition with canagliflozin. J Clin Pharmacol. 58(3):377–385. https ://doi.org/10.1002/jcph.1030 | eng |
| dcterms.references | Maeda S, Matsui T, Takeuchi M, Yamagishi S (2013) Sodium-glucose cotransporter 2-mediated oxidative stress augments advanced glycation end products-induced tubular cell apoptosis. Diabetes/ Metab Res Rev 29(5):406–412 | eng |
| dcterms.references | Goldenberg R, Berall M, Chan C, Cherney D, Lovshin J, McFarlane P, Weinstein J (2018) Managing the course of kidney disease in adults with type 2 diabetes: from the old to the new. Can J Diabetes 42(3):325–334 | eng |
| dcterms.references | Cherney D, Lund S, Perkins B, Groop P, Cooper M, Kaspers S, von Eynatten M (2016) The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia 59(9):1860–1870 | eng |
| dcterms.references | Zinman B, Wanner C, Lachin JM, Fitchett, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle H, Broedl UC, Inzucchi SE (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 373:2117–2128 | eng |
| dcterms.references | Ingelfinger J, Rosen C (2019) Clinical credence—SGLT2 inhibitors, diabetes, and chronic kidney disease. N Engl J Med 380(24):2371–2373. https ://doi.org/10.1056/NEJMe 19047 40 | eng |
| dcterms.references | Neal B, Perkovic V, Mahaffey K, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews D, Phil D (2017) Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 377:2097–2099. https: //doi.org/10.1056/ NEJMc 17125 72 | eng |
| dcterms.references | Wiviott S, Raz I, Bonaca M, Mosenzon O, Kato E, Cahn A, Silverman M, Zelniker T, Kuder J, Murphy S, Bhatt D, Leiter L, McGuire D, Wilding J, Ruff C, Gause-Nilsson I, Fredriksson M, Johansson P, Langkilde A, Sabatine M (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380:347–357. https ://doi.org/10.1056/nejmo a1812 389 | eng |
| dcterms.references | Vallon V, Richter K, Blantz RC, Thomson S, Osswald H (1999) Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J Am Soc Nephrol 10:2569–2576 | eng |
| dcterms.references | Bonnet F, Scheen AJ (2018) Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential contribution to diabetes complications and cardiovascular disease. Diabetes Metab. 44(6):457–464. https ://doi.org/10.1016/j.diabe t.2018.09.005 | eng |
| dcterms.references | Prattichizzo F, De Nigris V, Micheloni S, Sala L, Ceriello A Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: Is low-grade inflammation the neglected component. Diabetes Obes Metab 20(11): 2515–2522. https ://doi.org/10.1111/dom.13488 | eng |
| dcterms.references | Ashley C, Dunleavy A, Cunningham J (2019) The renal drug handbook. Taylor & Francis Group, New York | eng |
| dcterms.references | Szalat A, Perlman A, Muszkat M, Khamaisi M, Abassi Z, Heyman S (2017) Can SGLT2 inhibitors cause acute renal failure? Plausible role for altered glomerular hemodynamics and medullary hypoxia. Drug Saf 41(3):239–252 | eng |
| dcterms.references | Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 380(24):2295–2306. https ://doi.org/10.1056/NEJMo a1811 744 | eng |
| dcterms.references | Prattichizzo F, La Sala L, Rydén L, Marx N, Ferrini M, Valensi P, Ceriello A (2019) Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases. Eur J Prev Cardiol 26(2):73–80. https ://doi.org/10.1177/20474 87319 88004 0 | eng |
| oaire.version | info:eu-repo/semantics/publishedVersion | eng |